308 related articles for article (PubMed ID: 10861576)
1. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours.
Schulz S; Becker KF; Braungart E; Reichmuth C; Klamt B; Becker I; Atkinson M; Gessler M; Höfler H
J Pathol; 2000 Jun; 191(2):162-9. PubMed ID: 10861576
[TBL] [Abstract][Full Text] [Related]
2. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
3. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
4. Cadherins in Wilms' tumor: E-cadherin expression despite absence of WT1.
Baudry D; Cabanis MO; Patte C; Zucker JM; Pein F; Fournet JC; Sarnacki S; Junien C; Jeanpierre C
Anticancer Res; 2003; 23(1A):475-8. PubMed ID: 12680252
[TBL] [Abstract][Full Text] [Related]
5. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
[TBL] [Abstract][Full Text] [Related]
6. Functional loss of E-cadherin and cadherin-11 alleles on chromosome 16q22 in colonic cancer.
Braungart E; Schumacher C; Hartmann E; Nekarda H; Becker KF; Höfler H; Atkinson MJ
J Pathol; 1999 Apr; 187(5):530-4. PubMed ID: 10398117
[TBL] [Abstract][Full Text] [Related]
7. Genetic changes of the E-cadherin and APC tumour suppressor genes in clear cell renal cell carcinoma.
Pećina-SLaus N; Gall-TroSelj K; SLaus M; Radić K; NikuSeva-Martić T; Pavelić K
Pathology; 2004 Apr; 36(2):145-51. PubMed ID: 15203750
[TBL] [Abstract][Full Text] [Related]
8. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
[TBL] [Abstract][Full Text] [Related]
9. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.
Safford SD; Goyeau D; Freemerman AJ; Bentley R; Everett ML; Grundy PE; Skinner MA
Ann Surg Oncol; 2003 Mar; 10(2):136-43. PubMed ID: 12620908
[TBL] [Abstract][Full Text] [Related]
10. Molecular and cellular biology of Wilms' tumour.
Maitland NJ; Brown KW; Poirier V; Shaw AP; Williams J
Anticancer Res; 1989; 9(5):1417-26. PubMed ID: 2556071
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity at 7p in Wilms' tumour development.
Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
[TBL] [Abstract][Full Text] [Related]
13. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
Pritchard-Jones K; Fleming S
Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
[TBL] [Abstract][Full Text] [Related]
14. p57K1P2 is expressed in Wilms' tumor with LOH of 11p15.5.
Overall ML; Spencer J; Bakker M; Dziadek M; Smith PJ
Genes Chromosomes Cancer; 1996 Sep; 17(1):56-9. PubMed ID: 8889507
[TBL] [Abstract][Full Text] [Related]
15. The familial Wilms' tumour susceptibility gene, FWT1, may not be a tumour suppressor gene.
Rahman N; Arbour L; Tonin P; Baruchel S; Pritchard-Jones K; Narod SA; Stratton MR
Oncogene; 1997 Jun; 14(25):3099-102. PubMed ID: 9223674
[TBL] [Abstract][Full Text] [Related]
16. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer.
Huiping C; Sigurgeirsdottir JR; Jonasson JG; Eiriksdottir G; Johannsdottir JT; Egilsson V; Ingvarsson S
Br J Cancer; 1999 Dec; 81(7):1103-10. PubMed ID: 10584868
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
Wei Y; Van Nhieu JT; Prigent S; Srivatanakul P; Tiollais P; Buendia MA
Hepatology; 2002 Sep; 36(3):692-701. PubMed ID: 12198663
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour.
Grundy RG; Pritchard J; Scambler P; Cowell JK
Oncogene; 1998 Jul; 17(3):395-400. PubMed ID: 9690521
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
20. Expression and localization of HGF and met in Wilms' tumours.
Alami J; Williams BR; Yeger H
J Pathol; 2002 Jan; 196(1):76-84. PubMed ID: 11748645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
